Literature DB >> 26272345

Cell painting with an engineered EPCR to augment the protein C system.

Eveline A M Bouwens, Fabian Stavenuiter, Laurent O Mosnier1.   

Abstract

The protein C (PC) system conveys beneficial anticoagulant and cytoprotective effects in numerous in vivo disease models. The endothelial protein C receptor (EPCR) plays a central role in these pathways as cofactor for PC activation and by enhancing activated protein C (APC)-mediated protease-activated receptor (PAR) activation. During inflammatory disease, expression of EPCR on cell membranes is often diminished thereby limiting PC activation and APC's effects on cells. Here a caveolae-targeting glycosylphosphatidylinositol (GPI)-anchored EPCR (EPCR-GPI) was engineered to restore EPCR's bioavailability via "cell painting." The painting efficiency of EPCR-GPI on EPCR-depleted endothelial cells was time- and dose-dependent. The EPCR-GPI bioavailability after painting was long lasting since EPCR surface levels reached 400 % of wild-type cells after 2 hours and remained > 200 % for 24 hours. EPCR-GPI painting conveyed APC binding to EPCR-depleted endothelial cells where EPCR was lost due to shedding or shRNA. EPCR painting normalised PC activation on EPCR-depleted cells indicating that EPCR-GPI is functional active on painted cells. Caveolin-1 lipid rafts were enriched in EPCR after painting due to the GPI-anchor targeting caveolae. Accordingly, EPCR painting supported PAR1 and PAR3 cleavage by APC and augmented PAR1-dependent Akt phosphorylation by APC. Thus, EPCR-GPI painting achieved physiological relevant surface levels on endothelial cells, restored APC binding to EPCR-depleted cells, supported PC activation, and enhanced APC-mediated PAR cleavage and cytoprotective signalling. Therefore, EPCR-GPI provides a novel tool to restore the bioavailability and functionality of EPCR on EPCR- depleted and -deficient cells.

Entities:  

Keywords:  Endothelial protein C receptor; glycosylphosphatidylinositol anchors; protease-activated receptors; protein C; vascular endothelium

Mesh:

Substances:

Year:  2015        PMID: 26272345      PMCID: PMC5053618          DOI: 10.1160/TH15-01-0079

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  59 in total

Review 1.  The endothelial cell protein C receptor.

Authors:  C T Esmon
Journal:  Thromb Haemost       Date:  2000-05       Impact factor: 5.249

2.  Endothelial cell protein C receptor plays an important role in protein C activation in vivo.

Authors:  F B Taylor; G T Peer; M S Lockhart; G Ferrell; C T Esmon
Journal:  Blood       Date:  2001-03-15       Impact factor: 22.113

3.  sPLA2-V inhibits EPCR anticoagulant and antiapoptotic properties by accommodating lysophosphatidylcholine or PAF in the hydrophobic groove.

Authors:  Jacinto López-Sagaseta; Cristina Puy; Ibai Tamayo; Mikel Allende; Jorge Cerveró; Susana E Velasco; Charles T Esmon; Ramón Montes; José Hermida
Journal:  Blood       Date:  2011-12-13       Impact factor: 22.113

Review 4.  Activated protein C based therapeutic strategies in chronic diseases.

Authors:  Fabian Bock; Khurrum Shahzad; Nathalie Vergnolle; Berend Isermann
Journal:  Thromb Haemost       Date:  2014-03-20       Impact factor: 5.249

5.  Endothelial protein C receptor plasma levels increase in chronic liver disease, while thrombomodulin plasma levels increase only in hepatocellular carcinoma.

Authors:  Eugenia Biguzzi; Franca Franchi; Paolo Bucciarelli; Massimo Colombo; Raffaella Romeo
Journal:  Thromb Res       Date:  2006-10-17       Impact factor: 3.944

6.  Dysfunction of endothelial protein C activation in severe meningococcal sepsis.

Authors:  S N Faust; M Levin; O B Harrison; R D Goldin; M S Lockhart; S Kondaveeti; Z Laszik; C T Esmon; R S Heyderman
Journal:  N Engl J Med       Date:  2001-08-09       Impact factor: 91.245

7.  Protein C system defects inflicted by the malaria parasite protein PfEMP1 can be overcome by a soluble EPCR variant.

Authors:  Jens E V Petersen; Eveline A M Bouwens; Ibai Tamayo; Louise Turner; Christian W Wang; Monique Stins; Thor G Theander; José Hermida; Laurent O Mosnier; Thomas Lavstsen
Journal:  Thromb Haemost       Date:  2015-07-09       Impact factor: 5.249

8.  Hyperantithrombotic, noncytoprotective Glu149Ala-activated protein C mutant.

Authors:  Laurent O Mosnier; Antonella Zampolli; Edward J Kerschen; Reto A Schuepbach; Yajnavalka Banerjee; José A Fernández; Xia V Yang; Matthias Riewald; Hartmut Weiler; Zaverio M Ruggeri; John H Griffin
Journal:  Blood       Date:  2009-02-24       Impact factor: 22.113

9.  The alpha v beta 3 integrin as a tumor homing ligand for lymphocytes.

Authors:  Daniel F Legler; Caroline Johnson-Léger; Guido Wiedle; Claude Bron; Beat A Imhof
Journal:  Eur J Immunol       Date:  2004-06       Impact factor: 5.532

10.  Activation mechanism of anticoagulant protein C in large blood vessels involving the endothelial cell protein C receptor.

Authors:  K Fukudome; X Ye; N Tsuneyoshi; O Tokunaga; K Sugawara; H Mizokami; M Kimoto
Journal:  J Exp Med       Date:  1998-04-06       Impact factor: 14.307

View more
  5 in total

1.  Plasmodium falciparum var genes expressed in children with severe malaria encode CIDRα1 domains.

Authors:  Jakob S Jespersen; Christian W Wang; Sixbert I Mkumbaye; Daniel Tr Minja; Bent Petersen; Louise Turner; Jens Ev Petersen; John Pa Lusingu; Thor G Theander; Thomas Lavstsen
Journal:  EMBO Mol Med       Date:  2016-08-01       Impact factor: 12.137

2.  Biological Role of the Intercellular Transfer of Glycosylphosphatidylinositol-Anchored Proteins: Stimulation of Lipid and Glycogen Synthesis.

Authors:  Günter A Müller; Timo D Müller
Journal:  Int J Mol Sci       Date:  2022-07-04       Impact factor: 6.208

Review 3.  Biomedical applications of glycosylphosphatidylinositol-anchored proteins.

Authors:  Susanne Heider; John A Dangerfield; Christoph Metzner
Journal:  J Lipid Res       Date:  2016-08-19       Impact factor: 5.922

Review 4.  Predictors of outcome in childhood Plasmodium falciparum malaria.

Authors:  Harsita Patel; Claire Dunican; Aubrey J Cunnington
Journal:  Virulence       Date:  2020-12       Impact factor: 5.882

Review 5.  Pleiotropic actions of factor Xa inhibition in cardiovascular prevention: mechanistic insights and implications for anti-thrombotic treatment.

Authors:  Hugo Ten Cate; Tomasz J Guzik; John Eikelboom; Henri M H Spronk
Journal:  Cardiovasc Res       Date:  2021-07-27       Impact factor: 10.787

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.